Kunal Chaudhary
Nephrology · Columbia, MONPI 1528019809
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,722 of the $36,142 with a category attached, or 73.9%. Otsuka America Pharmaceutical, Inc. accounts for 92.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $22,892 and has fallen 98.2% since, to $420 in 2025. Among nephrology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $220.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$33K
- AstraZeneca$1K
- Amgen$327
- Travere Therapeutics, Inc.$286
- Calliditas Therapeutics US Inc.$140
- Vifor Pharma, Inc.$99
- plus $563 from 17 others
Across 67 payments — averaging $2234.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$116K
- AstraZeneca$32K
- Gilead$998
What the payments were for
- Speaking & faculty fees$26,72274%
- Travel & lodging$5,72616%
- Food & beverage$3,69110%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 85 | $33,331 |
| AstraZeneca | 13 | $1,396 |
| Amgen(2 entities) | 8 | $327 |
| Travere Therapeutics, Inc. | 20 | $286 |
| Calliditas Therapeutics US Inc. | 5 | $140 |
| Vifor Pharma, Inc. | 6 | $99 |
| Baxter Healthcare | 3 | $84 |
| Akebia Therapeutics Inc | 5 | $74 |
| Mallinckrodt Hospital Products Inc. | 4 | $73 |
| Novartis | 2 | $52 |
| Merck | 1 | $31 |
| Chiesi USA, Inc. | 1 | $31 |
| Apellis Pharmaceuticals, Inc. | 1 | $29 |
| Biobeat USA Inc. | 1 | $22 |
| Fresenius USA Marketing, Inc. | 1 | $22 |
| Vantive US Healthcare LLC | 1 | $21 |
| GSK | 1 | $21 |
| Ardelyx, Inc. | 1 | $20 |
| Sanofi | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Rockwell Medical, Inc. | 1 | $16 |
| Veloxis Pharmaceuticals, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,142 in reported general payments places this provider in the 90th percentile of 253 nephrology providers in Missouri.
Other nephrology in Columbia
- Zbylut TwardowskiColumbia$43K
- Preethi YerramColumbia$35K
- John VanstoneColumbia$28K
- Ramesh KhannaColumbia$14K
- Derek LarsonCreve Coeur$605K
- Marcos RothsteinSaint Louis$350K
- Anuja JavaSaint Louis$240K
- Kevin MartinSt Louis$189K
- Alejandro AlvarezFlorissant$176K
- Gary SingerSaint Peters$170K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.